We quantified the ADAM33-n expression level in the collected thyroid cancer biopsies and found that the aberration of ADAM33 in tumors is primarily attributable to the downregulation of ADAM33-n (Figure S1D). This evidence concerns the gene ADAM33 and thyroid gland carcinoma.